KOREA WHO
-
-
Founder of GemVax&KAEL
Kim Sang-jae
From Hospital Director to Stem Cell Entrepreneur, Aiming to Lead the KRW 20 Trillion Neurodegenerative Disease Market
-
Last Updated on Apr 4, 2025
-
Founder of GemVax&KAEL
Copy Url : https://www.koreawho.com/profile/KimSangjae- Life Summary
Kim Sang-jae is the founder of GemVax&KAEL (hereinafter referred to as GemVax).
After stepping down as CEO in 2024, he has remained as an advisor.
He is focusing on leading the KRW 20 trillion (US$ 14.4 billion) market for neurodegenerative disease treatments.
He was born on December 5, 1966.
He graduated from Kyung Sung High School in Seoul and Hanyang University College of Medicine. He studied spinal neurology at the University of Southern California in the United States and received both his master's and doctoral degrees in cellular physiology from Hanyang University Graduate School.
In 1995, he ran a clinic specializing in pediatric scoliosis in Apgujeong-dong, Seoul.
In 2005, he founded the Korea Stem Cell Bank, which extracts and stores stem cells. While searching for air filters for stem cell cultivation, he acquired KAEL, a KOSDAQ-listed semiconductor filter manufacturer, in 2007.
In October 2008, he acquired GEMVAX, a Norwegian biotechnology company owned by the Danish biopharmaceutical firm Pharmexa, and became CEO.
For 17 years, he has focused on developing the new drug candidate ‘GV1001.’
He is expanding its application to treat neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS).
#KimSangjae #GemVax #GV1001 #neurodegenerativedisease #Alzheimers #Parkinsons #stemcells #biotechstartup #Koreanbiotech #pharmaceuticals
After stepping down as CEO in 2024, he has remained as an advisor.
He is focusing on leading the KRW 20 trillion (US$ 14.4 billion) market for neurodegenerative disease treatments.
He was born on December 5, 1966.
He graduated from Kyung Sung High School in Seoul and Hanyang University College of Medicine. He studied spinal neurology at the University of Southern California in the United States and received both his master's and doctoral degrees in cellular physiology from Hanyang University Graduate School.
In 1995, he ran a clinic specializing in pediatric scoliosis in Apgujeong-dong, Seoul.
In 2005, he founded the Korea Stem Cell Bank, which extracts and stores stem cells. While searching for air filters for stem cell cultivation, he acquired KAEL, a KOSDAQ-listed semiconductor filter manufacturer, in 2007.
In October 2008, he acquired GEMVAX, a Norwegian biotechnology company owned by the Danish biopharmaceutical firm Pharmexa, and became CEO.
For 17 years, he has focused on developing the new drug candidate ‘GV1001.’
He is expanding its application to treat neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS).
#KimSangjae #GemVax #GV1001 #neurodegenerativedisease #Alzheimers #Parkinsons #stemcells #biotechstartup #Koreanbiotech #pharmaceuticals
- Life Summary
- Career Highlights & Challenges
- · GemVax's Ownership Structure
- · Increased R&D Expenses in Bio Division Widen Operating Loss
- · Clinical Trial Results for PSP Presented at International Conference
- · Paper on GV1001's Potential to Prevent Chemotherapy Side Effects Published in Journal
- · GV1001 Expected to Gain Accelerated FDA Approval
- · KAEL Succeeds in Localizing Korea’s Only Chemical Filter
- · Establishment of Stem Cell Bank
- · From Doctor to Bio-Venture Entrepreneur
- · History of GemVax
- Vision and Goals
- Market and Social Evaluation
- Notable Incidents & Legal Affairs
- Professional Timeline
- Educational Background
- Awards & Recognitions
- Additional Information
- Notable Quotations
- Infographic & Photos